Skip to content
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Menu
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Pipeline
SurVaxM
Clinical Trials
About
Leadership Team
News
Contact
Read more about the article Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

  • Post author:web-designer
  • Post published:July 25, 2016
  • Post category:Uncategorized

Immunotherapy Developed at Roswell Park Being Tested as Treatment for Multiple Myeloma BUFFALO, N.Y. — An immune-based therapy developed at Roswell Park Cancer Institute (RPCI) is moving forward with its…

Continue ReadingClinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

Recent Posts

  • Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy
  • MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
  • MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.
  • MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
  • MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Recent Comments

    Archives

    • February 2022
    • November 2021
    • May 2020
    • November 2019
    • October 2019
    • May 2019
    • March 2018
    • August 2017
    • July 2016
    • September 2015
    • April 2015

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    MimiVax, LLC

    info@mimivax.com

    Elm & Carlton Streets
    Buffalo, NY 14263

    Back to top
    Twitter Linkedin Youtube